基于纳米技术的药物输送平台的最新更新,用于用草药治疗阿尔茨海默氏症

相关实验视频

Updated: May 8, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.4K

Shakeel Ahmed Ansari¹, Asim Muhammad Alshanberi², Rukhsana Satar³

¹Department of Biochemistry, General Medicine Practice Program, Batterjee Medical College, Jeddah, Saudi Arabia.

Pharmaceutical nanotechnology

|December 24, 2024

概括

纳米技术增强了阿尔茨海默病 (AD) 的草药输送,克服了传统治疗的局限性. 纳米粒子提高了大脑的透率和有效性,为AD治疗提供了一个有前途的替代方案.

科学领域:

神经科学和药理学神经科学和药理学
生物医学工程和纳米技术

背景情况:

阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是记忆力丧失和认知能力下降.
目前的治疗方法,包括乙胆酶抑制剂 (AChEIs),面临着诸如血脑屏障 (BBB) 穿透性差,生物利用性低和不良副作用等挑战.
草药显示AD的治疗潜力,但患有有限的口服生物利用性.

研究的目的:

审查基于纳米技术的药物输送系统在阿尔茨海默病预防和治疗中的草药剂的进展.
探索纳米技术如何克服神经疾病常规草药药物的局限性.

主要方法:

对纳米技术应用的最新研究的审查,以提供诸如黄素,银杏花和Salvia officinalis之类的草药化合物,用于AD.
讨论各种纳米粒子系统,包括无机 (黄金,磁性) 和有机 (聚合物微粒,树脂,固体聚合物纳米粒子).
分析这些纳米粒子穿越血脑屏障 (BBB) 并提高大脑中药物度的能力.

主要成果:

纳米颗粒标记显著改善了针对AD的草药的大脑向性和生物可用性.
各种无机和有机纳米粒子系统在提高整个BBB的治疗草药剂的输送方面显示出潜力.
纳米技术提供了一种提高神经退行性疾病 (如AD) 草药治疗疗法的疗效的策略.

结论:

基于纳米技术的输送系统是增强阿尔茨海默病草药疗效的有希望的方法.
未来的战略必须专注于开发安全,无毒的纳米颗粒,以促进药物在BBB的运输,并进行有效的降解.
谨慎的配方至关重要,以确保纳米材料的安全性,防止长期积累,解决潜在的不良影响.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.药物输送是药物输送的过程.草药配方草药配方草药配方纳米技术.纳米技术.

相关概念视频

01:22

Alzheimer's Disease: Treatment

125

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

125

01:26

Alzheimer's Disease: Overview

313

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

313

01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.